Risk of posttransplant hepatocellular carcinoma recurrence is greater in recipients with higher platelet counts in living donor liver transplantation

Liver Transplantation

Volumn 24, Issue 1, 2018, Pages 44-55

  Han, Sangbin ^a   Lee, Sanghoon ^a   Yang, Ju Dong ^c   Leise, Michael Douglas ^c   Ahn, Joong Hyun ^b   Kim, Seonwoo ^b   Jung, Kangha ^a   Gwak, Mi Sook ^a   Kim, Gaab Soo ^a   Ko, Justin Sangwook ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Samsung Medical Center   (South Korea)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; BASILIXIMAB; ENTECAVIR; HEPATITIS B ANTIBODY; METHYLPREDNISOLONE; MYCOPHENOLATE MOFETIL; TACROLIMUS;

ADULT; ARTICLE; CANCER GRADING; CANCER RECURRENCE; FEMALE; GRAFT RECIPIENT; HEPATITIS B; HUMAN; INFLAMMATION; LIVER CELL CARCINOMA; LIVER METASTASIS; LIVER TRANSPLANTATION; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEUTROPHIL LYMPHOCYTE RATIO; PLATELET LYMPHOCYTE RATIO; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RECURRENCE RISK; RISK ASSESSMENT; RISK FACTOR; THROMBOCYTE COUNT; TUMOR INVASION; BLOOD; FOLLOW UP; KAPLAN MEIER METHOD; LIVER TUMOR; PATHOLOGY; PLATELET COUNT; PROCEDURES; PROPENSITY SCORE; TREATMENT OUTCOME; TUMOR RECURRENCE; YOUNG ADULT;

ADULT; CARCINOMA, HEPATOCELLULAR; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; LIVER TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PLATELET COUNT; PREOPERATIVE PERIOD; PROPENSITY SCORE; RISK FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85038577728     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.24961     Document Type: Article

References (39)

1. Han S, Kim G, Ko JS, Sinn DH, Yang JD, Joh JW, et al. Safety of the use of blood salvage and autotransfusion during liver transplantation for hepatocellular carcinoma. Ann Surg 2016;264:339-343.
2. Han S, Yang JD, Sinn DH, Kim JM, Choi GS, Jung G, et al. Risk of post-transplant hepatocellular carcinoma recurrence is higher in recipients of livers from male than female living donors. Ann Surg 2017; doi: 10.1097/SLA.0000000000002318.
3. Gawaz M, Vogel S. Platelets in tissue repair: control of apoptosis and interactions with regenerative cells. Blood 2013;122:2550-2554.
4. Leslie M. Beyond clotting: the powers of platelets. Science 2010;328:562-564.
5. Gay LJ, Felding-Habermann B. Contribution of platelets to tumour metastasis. Nat Rev Cancer 2011;11:123-134.
6. Tesfamariam B. Involvement of platelets in tumor cell metastasis. Pharmacol Ther 2016;157:112-119.
7. Buergy D, Wenz F, Groden C, Brockmann MA. Tumor-platelet interaction in solid tumors. Int J Cancer 2012;130:2747-2760.
8. Carr BI, Guerra V, Pancoska P. Thrombocytopenia in relation to tumor size in patients with hepatocellular carcinoma. Oncology 2012;83:339-345.
9. Lee CH, Lin YJ, Lin CC, Yen CL, Shen CH, Chang CJ, Hsieh SY. Pretreatment platelet count early predicts extrahepatic metastasis of human hepatoma. Liver Int 2015;35:2327-2336.
10. Bambace NM, Holmes C. The platelet contribution to cancer progression. J Thromb Haemost 2011;9:237-249.
11. Labelle M, Hynes RO. The initial hours of metastasis: the importance of cooperative host-tumor cell interactions during hematogenous dissemination. Cancer Discov 2012;2:1091-1099.
12. Sitia G, Aiolfi R, Di Lucia P, Mainetti M, Fiocchi A, Mingozzi F, et al. Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B. Proc Natl Acad Sci U S A 2012;109:E2165-E2172.
13. Han S, Ha SY, Park CK, Joh JW, Kwon CH, Kwon GY, et al. Microsteatosis may not interact with macrosteatosis in living donor liver transplantation. J Hepatol 2015;62:556-562.
14. Han S, Kwon JH, Jung SH, Seo JY, Jo YJ, Jang JS, et al. Perioperative fresh red blood cell transfusion may negatively affect recipient survival after liver transplantation. Ann Surg 2016. doi: 10.1097/SLA.0000000000002062.
15. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94:496-509.
16. Kim HT. Cumulative incidence in competing risks data and competing risks regression analysis. Clin Cancer Res 2007;13(pt 1):559-565.
17. Prado CM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L, Baracos V. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol 2008;9:629-635.
18. Han S, Yang JD, Sinn DH, Ko JS, Kim JM, Shin JC, et al. Higher bilirubin levels of healthy living liver donors are associated with lower posttransplant hepatocellular carcinoma recurrence. Transplantation 2016;100:1933-1938.
19. Rodríguez-Perálvarez M, Tsochatzis E, Naveas MC, Pieri G, García-Caparrós C, O'Beirne J, et al. Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma. J Hepatol 2013;59:1193-1199.
20. Parisi I, Tsochatzis E, Wijewantha H, Rodríguez-Perálvarez M, De Luca L, Manousou P, et al. Inflammation-based scores do not predict post-transplant recurrence of hepatocellular carcinoma in patients within Milan criteria. Liver Transpl 2014;20:1327-1335.
21. Gayat E, Resche-Rigon M, Mary JY, Porcher R. Propensity score applied to survival data analysis through proportional hazards models: a Monte Carlo study. Pharm Stat 2012;11:222-229.
22. Han S, Park HW, Song JH, Gwak MS, Lee WJ, Kim G, et al. Association between intraoperative platelet transfusion and early graft regeneration in living donor liver transplantation. Ann Surg 2016;264:1065-1072.
23. Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med 2009;28:3083-3107.
24. Zhang T, Sun HC, Xu Y, Zhang KZ, Wang L, Qin LX, et al. Overexpression of platelet-derived growth factor receptor alpha in endothelial cells of hepatocellular carcinoma associated with high metastatic potential. Clin Cancer Res 2005;11(pt 1):8557-8563.
25. Carr BI, Cavallini A, D'Alessandro R, Refolo MG, Lippolis C, Mazzocca A, Messa C. Platelet extracts induce growth, migration and invasion in human hepatocellular carcinoma in vitro. BMC Cancer 2014;14:43.
26. Clavien PA. Liver regeneration: a spotlight on the novel role of platelets and serotonin. Swiss Med Wkly 2008;138:361-370.
27. Morimoto Y, Nouso K, Wada N, Takeuchi Y, Kinugasa H, Miyahara K, et al. Involvement of platelets in extrahepatic metastasis of hepatocellular carcinoma. Hepatol Res 2014;44:E353-E359.
28. Dhanasekaran R, Venkatesh SK, Torbenson MS, Roberts LR. Clinical implications of basic research in hepatocellular carcinoma. J Hepatol 2016;64:736-745.
29. Peck-Radosavljevic M, Wichlas M, Zacherl J, Stiegler G, Stohlawetz P, Fuchsjäger M, et al. Thrombopoietin induces rapid resolution of thrombocytopenia after orthotopic liver transplantation through increased platelet production. Blood 2000;95:795-801.
30. Pradella P, Bonetto S, Turchetto S, Uxa L, Comar C, Zorat F, et al. Platelet production and destruction in liver cirrhosis. J Hepatol 2011;54:894-900.
31. Han S, Lee JH, Kim G, Ko JS, Choi SJ, Kwon JH, et al. Bioreactance is not interchangeable with thermodilution for measuring cardiac output during adult liver transplantation. PLoS One 2015;10:e0127981.
32. Stone RL, Nick AM, McNeish IA, Balkwill F, Han HD, Bottsford-Miller J, et al. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med 2012;366:610-618.
33. Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A; for OLT for HCC Consensu Group. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol 2012;13:e11-22.
34. Abiru S, Nakao K, Ichikawa T, Migita K, Shigeno M, Sakamoto M, et al. Aspirin and NS-398 inhibit hepatocyte growth factor-induced invasiveness of human hepatoma cells. Hepatology 2002;35:1117-1124.
35. Okada H, Honda M, Campbell JS, Sakai Y, Yamashita T, Takebuchi Y, et al. Acyclic retinoid targets platelet-derived growth factor signaling in the prevention of hepatic fibrosis and hepatocellular carcinoma development. Cancer Res 2012;72:4459-4471.
36. Hossain MA, Kim DH, Jang JY, Kang YJ, Yoon JH, Moon JO, et al. Aspirin induces apoptosis in vitro and inhibits tumor growth of human hepatocellular carcinoma cells in a nude mouse xenograft model. Int J Oncol 2012;40:1298-1304.
37. Clavien PA, Petrowsky H, DeOliveira ML, Graf R. Strategies for safer liver surgery and partial liver transplantation. N Engl J Med 2007;356:1545-1559.
38. Westerkamp AC, Lisman T, Porte RJ. How to minimize blood loss during liver surgery in patients with cirrhosis. HPB (Oxford) 2009;11:453-458.
39. Michalopoulos GK, DeFrances MC. Liver regeneration. Science 1997;276:60-66.